Corbus Pharmaceuticals Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $186.8M
- Price
- $10.38
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.15%
- Volume
- 604.0K
About
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Quick stats
Shares outstanding18.5M
Computed float15.9M
Float / shares85.9%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001595097
Websitehttps://www.corbuspharma.com
AI Summary
AI-generated1/19
minorbullishexecutive change
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Corbus Pharmaceuticals appointed Leonardo Nicacio as Chief Medical Officer, granting him inducement equity awards effective August 16, 2026.
The compensation package includes nonstatutory stock options for 191,676 shares at an exercise price of $10.09 and 58,333 restricted stock units, both subject to four-year vesting schedules.
Corbus is a clinical-stage biotech company focused on oncology and obesity therapies, including pipeline assets CRB-701 and CRB-913.
Red flags
- Grants issued outside of the Company's stockholder-approved equity compensation plans